Closing
Do GLP-1 receptor agonists improve cardiac & vascular function versus placebo?
Mostly studied in type 2 & unspecified diabetes.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, the results disagree.
NoUnsureYes
- Belief
- 0.50 (range 0.00–0.55)
- Trials for
- 3
- Trials against
- 1
- Inconclusive
- 3
Already under way
- GLIDE-HF Registry: A Prospective, Single-Center, Observational Cohort of Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction, With…NCT07787936 · not yet recruiting · started 2027
- Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthNCT06975111 · recruiting · started 2026
- Waiting on Atrial Fibrillation Intervention Therapy (WAIT) StudyNCT07275697 · recruiting · started 2026
- A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of 20-hydroxyecdysone (20E) in…NCT07411378 · not yet recruiting · started 2026
- DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNCT07483801 · not yet recruiting · started 2026
The evidence so far
- Registered trials
- 93
- With posted results
- 13
- Published papers
- 6
Of 20 decided analyses: 5 favor glp-1 receptor agonists, 14 find no difference, 1 favor the comparator.
Papers
- Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.Trial report · 2024
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.Trial report · 2017
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.Meta-analysis / systematic review · 2026
- GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.Meta-analysis / systematic review · 2025
- The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.Trial report · 2020
- Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.Trial report · 2017
Trials
- Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection FractionNCT04788511 · 14 posted results
- Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 DiabetesNCT04916470 · 2 posted results
- Effects of the Glucagon Like-peptide 1 (GLP-1) Receptor Agonist Liraglutide on Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: a Randomized Controlled TrialNCT04881110 · 1 posted result
- Functional Impact of GLP-1 for Heart Failure TreatmentNCT01800968 · 13 posted results
- Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes MellitusNCT01761318 · 1 posted result
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707
- Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized TrialNCT04122716
- Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412